Quick Takeaways
- Joseph S. Zakrzewski has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,613,148.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Joseph S. Zakrzewski
- Location
- New Hope, PA
- Summary
- The estimated net worth of Joseph S. Zakrzewski is at least $1,613,148 dollars as of 23 Mar 2026. Joseph S. Zakrzewski is the Director of AN2 Therapeutics, Inc. and owns shares of AN2 Therapeutics, Inc. (ANTX) stock worth about $739.5K. Joseph S. Zakrzewski is the Director of Cyteir Therapeutics, Inc. and owns shares of Cyteir Therapeutics, Inc. stock worth about $636.3K. Joseph S. Zakrzewski is the Director of AMARIN CORP PLC\UK and owns shares of AMARIN CORP PLC\UK (AMRN) stock worth about $214.2K. Joseph S. Zakrzewski is the Director of SANGAMO THERAPEUTICS, INC and owns shares of SANGAMO THERAPEUTICS, INC (SGMO) stock worth about $23.2K.
- Signature
- /s/ Lucy Day, Attorney-in-Fact for Joseph S. Zakrzewski
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Joseph S. Zakrzewski and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: AN2 Therapeutics, Inc. ($739,451).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Joseph S. Zakrzewski
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | Director | $739,451 | 19 Mar 2026 | ||
| CYT | Cyteir Therapeutics, Inc. | Director | $636,268 | 06 Feb 2024 | ||
| AMRN | AMARIN CORP PLC\UK | Director | $214,236 | 14 Dec 2021 | ||
| SGMO | SANGAMO THERAPEUTICS, INC | Director | $23,193 | 25 Feb 2022 | ||
| XLRN | ACCELERON PHARMA INC | Director | 19 Nov 2021 |
Insider Transactions Reported by Joseph S. Zakrzewski:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.